News
Screenings of Lung Cancer and COPD are Significant. What Do the Latest Data from Czechia Say?
At the end of January, an expert seminar was held, focusing on updates in the treatment of respiratory diseases. During this event, the head of the Pulmonary Clinic at LF UK and FN Hradec Králové, Associate Professor MUDr. Vladimír Koblížek, Ph.D., gave a lecture on the current Czech findings from lung cancer screenings and a project aimed at the early detection of chronic obstructive pulmonary disease (COPD).
Measurement of Serum Trough Levels of IgG as an Adequate and Beneficial Indicator for Assessing the Pharmacokinetics of Subcutaneously Administered Products
For many patients with primary immunodeficiency, lifelong immunoglobulin substitution is essential to...
Dosing and Consumption of rFVIII Products with Extended Half-life in Patients with Hemophilia A in Real-World Practice
Based on real-world data from the USA, a recently published study compared two recombinant human…
Ligamentous Changes as a Harbinger of Cardiac Amyloidosis – Histopathological and Clinical Study
Amyloid deposits can be present in various types of tissue. Their accumulation in connective tissue…
AAD 2023: Efficacy of Bimekizumab in the Treatment of Hidradenitis Suppurativa
At the latest annual congress of the American Academy of Dermatology (AAD), held March 17-22, 2023…
Efficacy and Safety of Ultrahypofractionated Proton Therapy in the Treatment of Prostate Cancer in Real-World Czech Practice
A team from the Prague Proton Therapy Center, led by Associate Professor Jiří Kubeš, published a…
Genetic Testing in Clinical Practice – An Irreplaceable Tool in Prevention, Diagnosis and Treatment
Genetic testing has long ceased to be the privilege of clinical research. In practice, it is commonly...
What Lies Behind ChatGPT? Artificial Intelligence with Potential Use Even in Clinical Medicine
ChatGPT, a program that enables conversation with sophisticated 'artificial intelligence', or…
Subcutaneous Immunoglobulin Substitution in Ig-Naive Patients with PID – Available Efficacy and Safety Data
The prevalence of primary immunodeficiencies (PID) is estimated at 1:10,000. Below, we summarize…
Bimekizumab in the Treatment of Psoriasis After Failure of (Not Only) Anti-IL-17A Antibodies – Case Reports
German authors last year described the first 2 cases of patients with psoriasis in whom treatment…